MEDINCELL overview

Regulatory News: Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information: About UZEDY ® 2024 sales: $117 million with $43 million in Q4 + 17% compared to $100 million updated Teva outlook in November 2025 Q1 Q2 Q3 Q4 $40 million $35 million $43 million Initial 2025 Teva outlook: $160 million vs. initial 2024 Teva outlook: $80 million Medincell receives mid- to high-single digit royalties on all sales and is eligible for $105 million of commercial...

Regulatory News: Medincell (Paris:MEDCL): Event Date Annual results 2024-2025 (April 2024-March 2025) Tuesday, June 17, 2025 General Meeting Thursday, September 11, 2025 Half-Year results 2025-2026 (April-September 2025) Tuesday, December 9, 2025 About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to...

Regulatory News: Medincell (Paris:MEDCL) joins the Euronext SBF 120 index, which includes the 120 largest companies listed on Euronext Paris, including the CAC 40 and most of the key players in the French economy. Medincell joins also the CAC Mid 60 index. Christophe Douat, CEO of Medincell, said: “Just six years after our IPO, Medincell joins the SBF 120, a recognition of our strength and performance. This milestone enhances our attractiveness to new French and international institutional...

Medincell (Paris:MEDCL) joins the Euronext SBF 120 index, which includes the 120 largest companies listed on Euronext Paris, including the CAC 40 and most of the key players in the French economy. Medincell joins also the CAC Mid 60 index. Christophe Douat, CEO of Medincell, said: “Just six years after our IPO, Medincell joins the SBF 120, a recognition of our strength and performance. This milestone enhances our attractiveness to new French and international institutional investors and will...

Regulatory News: Medincell (Paris:MEDCL): Key highlights Sales growth of UZEDY ® in the United States €2.8 million in royalties invoiced by Medincell over the period Upward revision of Teva's 2024 net sales forecast from $80 million to $100 million U.S. net sales year-to-date 2024: $75 million U.S. net sales in Q3 2024: $35 million Olanzapine LAI (mdc-TJK): positive results from the pivotal phase 3 trial Positive efficacy results announced in May 2024 No cases of post-injection...

Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed the following benefits when comparing patients treated with F14/mdc-CWM (n=51) to those in the control group (n=57) 1 : 70% reduction in the number of opioid users at 3 months post-surgery, 28% reduction in the total quantity of opioids consumed during the first 3 months post-surgery, Lower daily knee pain over the endpoints of 3 and 7...

Regulatory News: Medincell (Paris:MEDCL): Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed the following benefits when comparing patients treated with F14/mdc-CWM (n=51) to those in the control group (n=57) 1 : 70% reduction in the number of opioid users at 3 months post-surgery, 28% reduction in the total quantity of opioids consumed during the first 3 months post-surgery, Lower...

Regulatory News: Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 10 th , 2024 to present the half-year financial results (April 2024-September 2024) > Meeting in French, 6:00 pm (CET): https://www.medincell.com/fr/live-fr/ > Meeting in English, 7:00 pm (CET): https://www.medincell.com/live-en/ Shareholders are invited to send their questions to [email protected] , or through the chat system during the videoconference. About Medincell Medincell is a clinical- and...